CRP and liver cancer: Here, cytotoxicity as central readout of all the assays was positively correlated with a variety of cytotoxic and pro-inflammatory molecules that are also reflected by clinical data with cancer immunotherapy: IL-6 and CRP are increased in liver cancer patients developing immune-related adverse events following combination immunotherapy with PD-1 checkpoint inhibitors (86).